Abstract
BackgroundTwo IL-17A inhibitors are approved for the treatment of PsA, ixekizumab and secukinumab. At the time of this survey, real world evidence was only available for secukinumab, which was approved...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have